Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool

By Eleftherios P. Diamandis. Molecular & Cellular Proteomics, 2004

662 citations recorded by the source corpus.

Serum proteomic profiling, by using surfaced-enhanced laser desorption/ionization-time-of-flight mass spectrometry, is one of the most promising new approaches for cancer diagnostics. Exceptional sensitivities and specificities have been reported for some cancer types such as prostate, ovarian, breast, and bladder cancers. These sensitivities/specificities are far superior to those obtained by using classical cancer biomarkers. In this review, I concentrate more on questions that cast doubt on the results reported and propose experiments to investigate these questions in detail, before the technique is used at the clinic. It is clear that the method needs to be externally and thoroughly validated before clinical implementation is warranted.

Subfields: Molecular Biology, Spectroscopy

View Paper: https://www.semanticscholar.org/paper/719fbf9e95cb30442864a791d00c23d2282b1891

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Spectroscopy

Citations in the corpus

Statistical and Computational Methods for Comparative Proteomic Profiling Using Liquid Chromatography-Tandem Mass Spectrometry (2005, methodology): “A non-LC-based MS platform commonly used in profiling studies is SELDI (a refinement of MALDI), in which subsets of proteins in samples are selectively pre-adsorbed onto various proteomic chips (consisting of differing binding surfaces, such as hydrophobic or metal-binding surfaces) (8, 9).”
Point-of-care microfluidic devices for pathogen detection (2018, methodology): “SERS scattering (by Raman reporters) using gold, silver and QDs for signal enhancement can be achieved at very low concentration of cells (10−9 M).”
Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer (2004, background): “This limitation has been pointed out previously as being common among studies using mass spectrometry based proteomic profiling (25, 26, 38).”